Hyperlipoproteinemia, Type Iii (CAD)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Hyperlipoproteinemia, Type Iii

MalaCards integrated aliases for Hyperlipoproteinemia, Type Iii:

Name: Hyperlipoproteinemia, Type Iii 57 37
Coronary Artery Disease 74 37 29 55 6 43 63 17 72
Hyperlipoproteinemia Type Iii 12 75 74 55 44 15 72
Familial Type 3 Hyperlipoproteinemia 12 29 6
Floating-Betalipoproteinemia 57 74 72
Broad-Betalipoproteinemia 57 74 72
Hyperlipemia with Familial Hypercholesterolemic Xanthomatosis 57 74
Familial Hypercholesterolemia with Hyperlipemia 57 74
Familial Hyperbeta- and Prebetalipoproteinemia 57 74
Coronary Artery Disease, Severe 57 74
Dysbetalipoproteinemia Due to Defect in Apolipoprotein E-D 57
Dysbetalipoproteinemia Due to Defect in Apolipoprotein E 74
Coronary Artery Disease, Severe, Susceptibility to 57
Familial Hypercholesterolaemia with Hyperlipaemia 12
Apolipoprotein E, Deficiency or Defect of 57
Deficiency or Defect of Apolipoprotein E 74
Familial Hyperlipoproteinemia Type Iii 75
Carbohydrate Induced Hyperlipemia 12
Familial Dysbetalipoproteinemia 74
Familial Dyslipidemia Type 3 59
Remnant Hyperlipoproteinemia 59
Hyperlipoproteinemia Type 3 59
Coronary Arteriosclerosis 72
Coronary Heart Disease 72
Remnant Hyperlipidemia 12
Dysbetalipoproteinemia 59
Hyperlipoproteinemia 3 74
Hyperlipidemia Type 3 59
Broad Beta Disease 74
Broad-Beta Disease 59
Hlp Type 3 59
Hlpp3 74
Cad 74


Orphanet epidemiological data:

Inheritance: Autosomal dominant,Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;


External Ids:

Disease Ontology 12 DOID:3145
OMIM 57 617347
NCIt 50 C34710
SNOMED-CT 68 42569002
MESH via Orphanet 45 D006952
ICD10 via Orphanet 34 E78.2
UMLS via Orphanet 73 C0020479
Orphanet 59 ORPHA412
MedGen 42 C0020479
UMLS 72 C0010054 C0010068 C0020479 more

Summaries for Hyperlipoproteinemia, Type Iii

MedlinePlus : 43 Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Hyperlipoproteinemia, Type Iii, also known as coronary artery disease, is related to hyperlipoproteinemia, type iv and peripheral vascular disease, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Hyperlipoproteinemia, Type Iii is APOE (Apolipoprotein E), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Wnt signaling pathway. The drugs Nitric Oxide and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are hypertriglyceridemia and increased ldl cholesterol concentration

Disease Ontology : 12 A familial hyperlipidemia that has material basis in by homozygous, compound heterozygous, or heterozygous mutation in the APOE gene on chromosome 19q13.

OMIM : 57 Hyperlipoproteinemia type III, also called dysbetalipoproteinemia, is characterized by hyperlipidemia due to accumulation of remnants of the triglyceride (TG)-rich lipoproteins (TGRL), very low density lipoproteins (VLDL), and chylomicrons (CM), in response to dysfunctional genetic variants of apolipoprotein E or absence of apoE (summary by Blum, 2016). (617347)

KEGG : 37
Coronary artery disease (CAD) is one of the leading causes of death globally. CAD is coupled to a pathogenic process in which lipids and lipoproteins accumulate in the subendothelial intimal layer of the vessel wall. A variety of environmental and genetic risk factors are associated with CAD, including hypercholesterolemia, hypertension, obesity, diabetes, and a family history of early CAD. It has been reported that an autosomal dominant form of CAD is caused by the mutation in transcription factor MEF2A. A missense mutation in LRP6, which encodes a co-receptor in the Wnt signaling pathway, has also been identified.

UniProtKB/Swiss-Prot : 74 Coronary artery disease: A common heart disease characterized by reduced or absent blood flow in one or more of the arteries that encircle and supply the heart. Its most important complication is acute myocardial infarction. Hyperlipoproteinemia 3: A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

PubMed Health : 63 About coronary artery disease: Coronary artery disease (CAD, also called coronary heart disease, or CHD) is caused by the narrowing of the large blood vessels that supply the heart with oxygen. These are called coronary arteries. Arteries that have become extremely narrow can cause shortness of breath and chest pain during physical activity. If a coronary artery suddenly becomes completely blocked, it can result in a heart attack. CAD can also lead to other health problems like heart failure or heart rhythm problems. Various treatments can be used to reduce the symptoms and the risk of complications.

Wikipedia : 75 Familial dysbetalipoproteinemia or type III hyperlipoproteinemia is a condition characterized by... more...

Related Diseases for Hyperlipoproteinemia, Type Iii

Diseases in the Hyperlipoproteinemia, Type Iii family:

Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hyperlipoproteinemia, Type I Hyperlipoproteinemia, Type Id

Diseases related to Hyperlipoproteinemia, Type Iii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 889)
# Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia, type iv 32.2 LPL APOC2 APOB APOA5
2 peripheral vascular disease 31.7 LPA APOB APOA1
3 tangier disease 31.5 LPL LPA CETP APOE APOB APOA1
4 hyperalphalipoproteinemia 1 31.1 LPL LIPC LDLR CETP APOE APOB
5 hypertension, essential 30.8 LPL LPA APOB APOA1
6 arteriosclerosis 30.8 LPA HMGCR COG2 APOE APOB APOA1
7 cerebral atherosclerosis 30.7 APOE APOA1
8 aortic atherosclerosis 30.6 LPA LDLR CETP APOE
9 coronary stenosis 30.4 CETP APOE APOB APOA1
10 macular degeneration, age-related, 1 30.3 LIPC CETP APOE APOB
11 carotid artery disease 30.2 LPA COG2 APOE APOB APOA1
12 apolipoprotein c-ii deficiency 30.1 LPL APOC2
13 hyperlipoproteinemia, type v 30.1 LPL HMGCR APOE APOC2 APOB APOA5
14 arteries, anomalies of 29.9 LPA LDLR COG2 CETP APOE APOB
15 hepatic lipase deficiency 29.9 LPL LIPC APOE APOA1
16 cerebrovascular disease 29.8 LDLR APOE APOB APOA1
17 prediabetes syndrome 29.8 COG2 APOB
18 pancreatitis 29.8 LPL APOC2 APOA5
19 gallbladder disease 29.7 CETP APOE APOB APOA1
20 inherited metabolic disorder 29.7 COG2 APOB APOA1
21 hypolipoproteinemia 29.7 LPL LPA APOE APOB APOA1
22 stroke, ischemic 29.4 LPA HMGCR COG2 APOE APOB
23 defective apolipoprotein b-100 29.3 LDLR HMGCR APOE APOB
24 abetalipoproteinemia 29.3 LPL LDLR CETP APOE APOB APOA1
25 atherosclerosis susceptibility 29.1 LPA LDLR CETP APOE APOB APOA1
26 heart disease 29.0 LPL LDLR APOE APOB APOA5 APOA1
27 homozygous familial hypercholesterolemia 29.0 LIPC LDLR HMGCR APOE APOB
28 xanthomatosis 28.6 LPL LPA LDLR HMGCR APOE APOB
29 coronary artery anomaly 28.6 LPL LPA HMGCR COG2 CETP APOB
30 arcus corneae 28.4 LPA LDLR COG2 CETP APOE APOB
31 hypertriglyceridemia, familial 28.2 LPL LIPC CETP APOE APOC2 APOB
32 body mass index quantitative trait locus 11 28.0 LPL LPA LIPC LDLR COG2 CETP
33 vascular disease 27.6 LPL LPA LDLR HMGCR CETP APOE
34 diabetes mellitus, noninsulin-dependent 27.3 LPL LPA LIPC HMGCR COG2 CETP
35 diabetes mellitus 27.0 LPL LPA LIPC HMGCR COG2 APOB
36 myocardial infarction 26.6 LPA LDLR HMGCR COG2 CETP APOE
37 lipid metabolism disorder 26.3 LPL LPA LIPC LDLR HMGCR COG2
38 coronary heart disease 1 26.3 LPL LPA LIPC LDLR HMGCR COG2
39 familial hyperlipidemia 26.3 LPL LPA LIPC LDLR HMGCR COG2
40 coronary artery disease, autosomal dominant, 1 12.9
41 coronary artery disease, autosomal dominant 2 12.7
42 abdominal obesity-metabolic syndrome 3 12.0
43 coronary heart disease 5 11.9
44 hyperlipidemia type 3 11.9
45 sitosterolemia 11.7
46 hypoalphalipoproteinemia 11.6
47 hypoalphalipoproteinemia, primary, 1 11.6
48 hypercholesterolemia, familial, 2 11.6
49 hypercholesterolemia, familial, 3 11.4
50 hypercholesterolemia, familial, 4 11.3

Graphical network of the top 20 diseases related to Hyperlipoproteinemia, Type Iii:

Diseases related to Hyperlipoproteinemia, Type Iii

Symptoms & Phenotypes for Hyperlipoproteinemia, Type Iii

Human phenotypes related to Hyperlipoproteinemia, Type Iii:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertriglyceridemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002155
2 increased ldl cholesterol concentration 59 32 hallmark (90%) Very frequent (99-80%) HP:0003141
3 hypercholesterolemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003124
4 decreased hdl cholesterol concentration 59 32 hallmark (90%) Very frequent (99-80%) HP:0003233
5 obesity 59 32 frequent (33%) Frequent (79-30%) HP:0001513
6 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
7 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
8 hepatic steatosis 59 32 frequent (33%) Frequent (79-30%) HP:0001397
9 corneal arcus 59 32 frequent (33%) Frequent (79-30%) HP:0001084
10 xanthelasma 59 32 frequent (33%) Frequent (79-30%) HP:0001114
11 tendon xanthomatosis 59 32 frequent (33%) Frequent (79-30%) HP:0010874
12 type iv atherosclerotic lesion 32 frequent (33%) HP:0002635
13 hypothyroidism 59 32 occasional (7.5%) Occasional (29-5%) HP:0000821
14 angina pectoris 59 32 occasional (7.5%) Occasional (29-5%) HP:0001681
15 gout 59 32 occasional (7.5%) Occasional (29-5%) HP:0001997
16 accelerated atherosclerosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004943
17 renal steatosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000799
18 acute pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001735
19 peripheral arterial stenosis 32 occasional (7.5%) HP:0004950
20 premature coronary artery atherosclerosis 32 occasional (7.5%) HP:0005181
21 aortic atherosclerotic lesion 32 occasional (7.5%) HP:0012397
22 abnormality of the skin 59 Very frequent (99-80%)
23 premature coronary artery disease 59 Occasional (29-5%)
24 atheromatosis 59 Frequent (79-30%)
25 peripheral arterial disease 59 Occasional (29-5%)
26 premature peripheral vascular disease 59 Occasional (29-5%)
27 aortic atherosclerosis 59 Occasional (29-5%)

Clinical features from OMIM:


UMLS symptoms related to Hyperlipoproteinemia, Type Iii:

tremor, angina pectoris, edema, chest pain, equilibration disorder, substernal pain

GenomeRNAi Phenotypes related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOE CETP HMGCR
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE LDLR LPL

MGI Mouse Phenotypes related to Hyperlipoproteinemia, Type Iii:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.65 APOA1 APOA5 APOB APOC2 APOE COG2
2 liver/biliary system MP:0005370 9.1 APOA1 APOB APOE HMGCR LDLR LPL

Drugs & Therapeutics for Hyperlipoproteinemia, Type Iii

PubMed Health treatment related to Hyperlipoproteinemia, Type Iii: 63

The main goals of treatment for CAD are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina. Beta blockers, calcium channel blockers and nitrates are used for this purpose. If that doesn't help, doctors often try to widen the narrowed coronary artery with a procedure using a cardiac catheter. If the arteries are severely narrowed, or if several blood vessels are affected, bypass surgery may be considered. This involves taking a blood vessel from elsewhere in the body and using it to redirect blood around the blocked coronary artery (bypassing it). There are things you can do on your own to help prevent complications like a heart attack or heart failure: eating a healthy diet and getting enough exercise are two examples. If you smoke, you could try to give it up. Also, there are a number of different medications that can prevent complications and increase life expectancy. These include the following: Low doses of acetylsalicylic acid (the drug in medicines like "Aspirin") to prevent blood clotsStatins to protect the blood vesselsBeta blockers to reduce the strain on the heart (especially in people with heart failure or high blood pressure)

Drugs for Hyperlipoproteinemia, Type Iii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 963)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Nitric Oxide Approved Phase 4 10102-43-9 145068
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Coal tar Approved Phase 4 8007-45-2
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Ticlopidine Approved Phase 4 55142-85-3 5472
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
Dobutamine Approved Phase 4 34368-04-2 36811
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Cosyntropin Approved Phase 4 16960-16-0 16129617
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Etomidate Approved Phase 4 33125-97-2 36339 667484
Histamine Approved, Investigational Phase 4 51-45-6 774
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Nifedipine Approved Phase 4 21829-25-4 4485
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Famotidine Approved Phase 4 76824-35-6 3325
Norepinephrine Approved Phase 4 51-41-2 439260
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Edoxaban Approved Phase 4 480449-70-5
Remifentanil Approved Phase 4 132875-61-7 60815
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Saxagliptin Approved Phase 4 361442-04-8 11243969
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Citalopram Approved Phase 4 59729-33-8 2771

Interventional clinical trials:

(show top 50) (show all 6252)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
4 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
5 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
6 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
7 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
8 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
9 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
10 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
11 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
13 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
14 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
15 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
16 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
17 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
18 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
19 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
20 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
21 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
22 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
23 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
24 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
25 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
26 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
27 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
28 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
29 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
30 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
31 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
32 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
33 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
34 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
35 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
36 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
37 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
38 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
39 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
40 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
41 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
42 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
43 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
44 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
45 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
46 Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial Unknown status NCT01609725 Phase 4
47 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
48 The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions) Unknown status NCT01375465 Phase 4
49 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
50 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C

Search NIH Clinical Center for Hyperlipoproteinemia, Type Iii

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Atorvastatin calcium
Cerivastatin sodium
Cholestyramine Resin
Colesevelam hydrochloride
Colestipol Hydrochloride
Dextrothyroxine Sodium
Fish Liver Oils
Fluvastatin sodium
Isosorbide Dinitrate
Isosorbide Mononitrate
Pravastatin Sodium

Cochrane evidence based reviews: hyperlipoproteinemia type iii

Genetic Tests for Hyperlipoproteinemia, Type Iii

Genetic tests related to Hyperlipoproteinemia, Type Iii:

# Genetic test Affiliating Genes
1 Familial Type 3 Hyperlipoproteinemia 29 APOE
2 Coronary Artery Disease 29

Anatomical Context for Hyperlipoproteinemia, Type Iii

MalaCards organs/tissues related to Hyperlipoproteinemia, Type Iii:

Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Hyperlipoproteinemia, Type Iii

Articles related to Hyperlipoproteinemia, Type Iii:

(show top 50) (show all 30142)
# Title Authors PMID Year
Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. 38 8 71
7175379 1982
Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance. 8 71
2313204 1990
The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene. 8 71
3029073 1987
Familial apolipoprotein E deficiency. 8 71
3771793 1986
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. 8 71
6313758 1983
Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. 8 71
6795720 1981
Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. 9 71
16143024 2005
Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. 9 71
9649566 1998
Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). 9 71
7635945 1995
Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. 9 71
1361196 1992
Apolipoprotein epsilon 4 and coronary artery disease. 38 8
1360057 1992
Apolipoprotein epsilon 4 and coronary artery disease. 38 8
1360061 1992
Apolipoprotein epsilon 4 and coronary artery disease. 38 8
1360062 1992
Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype. 9 71
1360898 1992
The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. 9 71
1730728 1992
Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. 38 71
3721502 1986
A meta-analysis on the association of genetic polymorphism of the angiotensin-converting enzyme and coronary artery disease in the chinese population. 38 17
31340327 2019
Microcirculation function assessed by adenosine triphosphate stress myocardial contrast echocardiography and prognosis in patients with nonobstructive coronary artery disease. 38 17
31277090 2019
Type III Hyperlipoproteinemia: Still Worth Considering? 8
27481046 2016
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. 71
22962670 2012
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. 8
18334912 2008
Polymorphisms associated with cholesterol and risk of cardiovascular events. 8
18354102 2008
Subsets of SNPs define rare genotype classes that predict ischemic heart disease. 8
17006673 2007
Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. 71
15096402 2004
Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia. 8
8911609 1996
Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis. 71
8664327 1996
Genetic associations with human longevity at the APOE and ACE loci. 8
8136829 1994
Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. 71
8488843 1993
Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. 8
1357300 1992
Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia. 71
1356443 1992
Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. 71
1674745 1991
Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi). 71
2101409 1990
Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. 71
2556398 1989
Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease. 8
2791332 1989
Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. 71
2539388 1989
Genotyping and sequence analysis of apolipoprotein E isoforms. 71
3243553 1988
Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. 8
3337104 1988
Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue. 8
3690877 1987
Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. 71
3038959 1987
ApoE deficiency: markedly decreased levels of cellular ApoE mRNA. 8
3004475 1986
Isolation and characterisation of a variant allele of the gene for human apolipoprotein E. 71
2992507 1985
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. 8
6309907 1983
Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. 8
6309903 1983
Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. 71
6860421 1983
Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. 71
6300187 1983
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. 8
6289314 1982
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. 8
6270194 1981
Regulation of plasma cholesterol by lipoprotein receptors. 8
6261329 1981
Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. 8
7455696 1981
Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia. 8
7464557 1981

Variations for Hyperlipoproteinemia, Type Iii

ClinVar genetic disease variations for Hyperlipoproteinemia, Type Iii:

6 (show all 16)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE): c.388T> C (p.Cys130Arg) single nucleotide variant other rs429358 19:45411941-45411941 19:44908684-44908684
2 APOE NM_000041.4(APOE): c.488G> A (p.Arg163His) single nucleotide variant Pathogenic rs121918397 19:45412041-45412041 19:44908784-44908784
3 APOE NM_000041.4(APOE): c.460C> A (p.Arg154Ser) single nucleotide variant Pathogenic rs121918393 19:45412013-45412013 19:44908756-44908756
4 APOE NM_000041.4(APOE): c.487C> T (p.Arg163Cys) single nucleotide variant Pathogenic rs769455 19:45412040-45412040 19:44908783-44908783
5 APOE NM_000041.4(APOE): c.237-2A> G single nucleotide variant Pathogenic rs397514253 19:45411788-45411788 19:44908531-44908531
6 APOE NM_000041.4(APOE): c.415_435dup (p.Glu139_Gly145dup) duplication Pathogenic rs397514254 19:45411968-45411988 19:44908711-44908731
7 APOE NM_000041.4(APOE): c.490A> G (p.Lys164Glu) single nucleotide variant Pathogenic rs121918394 19:45412043-45412043 19:44908786-44908786
8 APOE NM_000041.4(APOE): c.490A> C (p.Lys164Gln) single nucleotide variant Pathogenic rs121918394 19:45412043-45412043 19:44908786-44908786
9 APOE NM_000041.4(APOE): c.91G> A (p.Glu31Lys) single nucleotide variant Pathogenic rs201672011 19:45411064-45411064 19:44907807-44907807
10 APOE APOE, 1-BP DEL, 2919G deletion Pathogenic
11 APOE NM_000041.4(APOE): c.683G> A (p.Trp228Ter) single nucleotide variant Pathogenic rs121918396 19:45412236-45412236 19:44908979-44908979
12 APOE NM_000041.2(APOE): c.526C> T (p.Arg176Cys) single nucleotide variant drug response rs7412 19:45412079-45412079 19:44908822-44908822
13 APOE NM_000041.4(APOE): c.478C> T (p.Arg160Cys) single nucleotide variant no interpretation for the single variant rs387906567 19:45412031-45412031 19:44908774-44908774
14 APOE NM_000041.2(APOE): c.725G> A (p.Arg242Gln) single nucleotide variant no interpretation for the single variant rs267606663 19:45412278-45412278 19:44909021-44909021
15 APOE NM_000041.4(APOE): c.761T> A (p.Val254Glu) single nucleotide variant no interpretation for the single variant rs199768005 19:45412314-45412314 19:44909057-44909057
16 APOE NM_000041.4(APOE): c.805C> G (p.Arg269Gly) single nucleotide variant no interpretation for the single variant rs267606661 19:45412358-45412358 19:44909101-44909101

UniProtKB/Swiss-Prot genetic disease variations for Hyperlipoproteinemia, Type Iii:

# Symbol AA change Variation ID SNP ID
1 APOE p.Glu31Lys VAR_000646 rs201672011
2 APOE p.Cys130Arg VAR_000652 rs429358
3 APOE p.Arg154Ser VAR_000656 rs121918393
4 APOE p.Arg154Cys VAR_000657 rs121918393
5 APOE p.Arg160Cys VAR_000658 rs387906567
6 APOE p.Arg163Cys VAR_000659 rs769455
7 APOE p.Lys164Gln VAR_000661 rs121918394
8 APOE p.Lys164Glu VAR_000662 rs121918394
9 APOE p.Arg176Cys VAR_000664 rs7412

Expression for Hyperlipoproteinemia, Type Iii

Search GEO for disease gene expression data for Hyperlipoproteinemia, Type Iii.

Pathways for Hyperlipoproteinemia, Type Iii

Pathways related to Hyperlipoproteinemia, Type Iii according to KEGG:

# Name Kegg Source Accession
1 cGMP-PKG signaling pathway hsa04022
2 Wnt signaling pathway hsa04310

Pathways related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 11.76 APOE APOA5 APOA1
Show member pathways
8 11.49 LPL APOA5 APOA1
Show member pathways
11 11.04 LDLR APOE
12 10.94 APOA5 APOA1
13 10.89 APOB APOA1
14 10.77 LDLR HMGCR

GO Terms for Hyperlipoproteinemia, Type Iii

Cellular components related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.88 LIPC APOE APOB APOA5 APOA1
2 early endosome GO:0005769 9.85 LDLR APOE APOC2 APOB APOA1
3 high-density lipoprotein particle GO:0034364 9.73 LIPC CETP APOE APOC2 APOA5 APOA1
4 clathrin-coated endocytic vesicle membrane GO:0030669 9.67 LDLR APOE APOB
5 very-low-density lipoprotein particle GO:0034361 9.63 LPL APOE APOC2 APOB APOA5 APOA1
6 intermediate-density lipoprotein particle GO:0034363 9.62 APOE APOC2 APOB APOA1
7 endocytic vesicle lumen GO:0071682 9.61 APOE APOB APOA1
8 spherical high-density lipoprotein particle GO:0034366 9.52 APOC2 APOA1
9 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
10 low-density lipoprotein particle GO:0034362 9.43 LDLR APOE APOC2 APOB APOA5 APOA1
11 chylomicron GO:0042627 9.1